Multiple Sclerosis in America 2026
Multiple sclerosis (MS) stands as one of the most common disabling neurological conditions affecting young and middle-aged adults across the United States. As a chronic, immune-mediated disease of the central nervous system, MS damages the protective myelin sheath surrounding nerve fibers, disrupting communication between the brain, spinal cord, and the rest of the body. This results in a wide-ranging set of symptoms — from fatigue and balance problems to vision disturbances and mobility challenges — that can fluctuate unpredictably or progress steadily over time. A landmark study funded by the National Multiple Sclerosis Society (NMSS), developed in partnership with the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH), found that nearly 1 million Americans are living with MS — more than double the previously accepted estimate of approximately 400,000 that had stood for decades.
What makes the 2026 multiple sclerosis landscape particularly significant is the way updated epidemiological methods have reshaped scientific understanding of who develops the disease. While MS was long considered a condition predominantly affecting white women of Northern European descent, newer NIH and NMSS-funded research published in JAMA Neurology has revealed substantially higher prevalence among Black Americans than previously recognized, alongside a heavier disease course in this population. Combined with a staggering $85.4 billion annual economic burden and a treatment landscape dominated by increasingly expensive disease-modifying therapies, MS represents both a profound personal health challenge and a significant national policy concern. This article draws exclusively on verified data from US government-funded research and major peer-reviewed neurology journals to present the most accurate and current statistical picture of multiple sclerosis in the United States in 2026.
Multiple Sclerosis Key Facts in the US 2026
Before exploring detailed statistical breakdowns, the following key facts establish the foundational scope and severity of multiple sclerosis nationally.
MULTIPLE SCLEROSIS KEY FACTS SNAPSHOT — US 2026
=================================================
Total US MS Cases ████████████████████ ~1 million
US Prevalence Rate ████████████████░░░░ ~362 per 100,000
New Diagnoses Per Week ████████░░░░░░░░░░░░ 450+ (US)
Female Share of Cases ████████████████████ 74%
Peak Diagnosis Age ████████████░░░░░░░░ 20–50 years
Avg US Diagnosis Age ████████░░░░░░░░░░░░ 36 years
Annual Economic Burden ████████████████████ $85.4 billion
Avg Per-Patient Cost ████████████████░░░░ $88,487/year
| Key Fact | Detail |
|---|---|
| Total Americans living with MS | Nearly 1 million (851,749–913,925 estimated range) |
| US prevalence rate (2017 estimate) | 362 per 100,000 people |
| Prevalence rise since 1976 | From 58 per 100,000 to current levels — a six-fold increase |
| New diagnoses per week (US) | More than 450 people |
| Female share of US MS cases | 74% |
| Male share of US MS cases | 26% |
| Female-to-male risk ratio | 3x greater risk for women (JAMA Neurology, 2023) |
| Typical age of diagnosis range | 20–50 years |
| Average US diagnosis age | 36 years |
| Primary progressive MS share | 10–15% of all MS patients |
| Total US economic burden (2019) | $85.4 billion annually |
| Average per-patient annual cost | $88,487 |
Source: National Multiple Sclerosis Society (NMSS)-funded national prevalence study, published in Neurology, 2019 (NIH/CDC-supported methodology); Hittle M et al., JAMA Neurology, 2023; Bebo B et al., Neurology, 2022
The discovery that nearly 1 million Americans live with MS — roughly double the long-cited figure of 400,000 — represents one of the most consequential epidemiological revisions in recent neurology research. This finding emerged from a rigorous NMSS-led Prevalence Workgroup, which applied a validated case-identification algorithm to multiple large administrative health claims datasets, including private insurance, military health records, and public payer data such as Medicare and Medicaid. The resulting estimate of 403,630 cases extrapolated using improved methodology ultimately revealed a true national burden far larger than earlier studies had captured, underscoring how methodological advances — rather than necessarily a true rise in disease incidence — can dramatically reshape public health understanding.
The economic scale of MS is equally striking. With an estimated $85.4 billion total annual economic burden and an average per-patient cost of $88,487 per year, multiple sclerosis ranks among the most expensive chronic neurological conditions per capita in the United States. This cost burden is overwhelmingly driven by the rising price of disease-modifying therapies (DMTs), which have transformed disease outcomes for many patients but have also placed mounting financial strain on individuals, insurers, and the federal healthcare system alike.
Multiple Sclerosis Prevalence by Race and Ethnicity in the US 2024
Racial and ethnic disparities in multiple sclerosis prevalence have been substantially revised by recent NIH and NMSS-funded population-based research, challenging decades-old assumptions about who is most affected by this disease.
MULTIPLE SCLEROSIS PREVALENCE BY RACE/ETHNICITY — US 2024
=============================================================
(Cumulative 10-year prevalence per 100,000 adults, 2010 data)
White ████████████████████ 374.8 per 100,000
Black ████████████████░░░░ 298.4 per 100,000
Other races (non-Hisp)████████████░░░░░░░░ 197.7 per 100,000
Hispanic ████████░░░░░░░░░░░░ 161.2 per 100,000
Female:Male ratio overall: 2.9:1
| Racial/Ethnic Group | Prevalence per 100,000 | Notes |
|---|---|---|
| Non-Hispanic White | 374.8 | Highest overall prevalence |
| Black Americans | 298.4 | Second-highest; long underrecognized |
| Other non-Hispanic groups | 197.7 | Includes Asian, Native American, multiracial |
| Hispanic Americans | 161.2 | Lowest of the four major groups studied |
| MS occurrence (per 1,000), White | ~4 in 1,000 | UMSOM/NMSS analysis |
| MS occurrence (per 1,000), Black | ~3 in 1,000 | UMSOM/NMSS analysis |
| MS occurrence (per 1,000), Other races | ~2 in 1,000 | UMSOM/NMSS analysis |
| MS occurrence (per 1,000), Hispanic | ~1.5 in 1,000 | UMSOM/NMSS analysis |
| Female-to-male ratio (overall, 2010 data) | 2.9 : 1 | JAMA Neurology, 2023 |
Source: Hittle M, Culpepper WJ, Langer-Gould A, et al., JAMA Neurology, 2023 (NMSS/NIH-funded, University of Maryland School of Medicine-led); Wallin MT et al., Neurology, 2019
The JAMA Neurology study, led by researchers affiliated with the University of Maryland School of Medicine and funded by the National Multiple Sclerosis Society, fundamentally revised the racial epidemiology of MS in America. While non-Hispanic White Americans still record the highest overall prevalence at 374.8 per 100,000, the data confirms that Black Americans follow closely at 298.4 per 100,000 — a rate considerably higher than historical assumptions suggested. This finding aligns with a growing body of NIH-supported research demonstrating that MS has long been underrecognized in the Black community, likely due to a combination of diagnostic bias, unequal access to neurological specialists, and historically limited representation in MS research cohorts.
Hispanic Americans recorded the lowest prevalence among the four groups studied, at 161.2 per 100,000, though researchers note this may partly reflect lower healthcare-seeking behavior or diagnostic delays rather than true biological immunity to the disease. Critically, separate NIH and NMSS-funded clinical research has found that Black patients with MS tend to experience a more aggressive disease course, including a higher likelihood of optic nerve and spinal cord involvement at diagnosis, frequent relapses, and earlier accumulation of disability compared to white patients. This combination of higher-than-expected prevalence and worse clinical outcomes among Black Americans represents one of the most pressing equity concerns in contemporary MS care and research funding priorities.
Multiple Sclerosis by Age, Sex and Geography in the US 2024
Age, biological sex, and geographic latitude all play substantial, well-documented roles in determining who develops multiple sclerosis and where in the country they are most likely to be diagnosed.
MULTIPLE SCLEROSIS BY AGE GROUP AND REGION — US 2024
=======================================================
Peak prevalence age range (45–64) ████████████████████ ~50% of all cases
Female peak prevalence age (45–54) ████████████████░░░░ Highest in this band
Male peak prevalence age (55–64) ████████████████░░░░ Highest in this band
MS PREVALENCE BY US LATITUDE (per 100,000):
Southern US (Texas, ~33°N) ████████░░░░░░░░░░░░ 47.2
Central US (Missouri, ~39°N) ████████████████░░░░ 86.3
Northern US (Ohio, ~41°N) ████████████████████ 109.5
| Demographic Factor | Statistic | Source |
|---|---|---|
| Patients aged 45–64 years | Nearly 50% of all MS cases | JAMA Neurology, 2023 |
| Female peak prevalence age | 45–54 years | JAMA Neurology, 2023 |
| Male peak prevalence age | 55–64 years | JAMA Neurology, 2023 |
| Typical age range at diagnosis | 20–50 years | NMSS/NIH-funded data |
| Average US age at diagnosis | 36 years | Atlas of MS/NMSS data |
| Southern US prevalence (Texas, ~33°N) | 47.2 per 100,000 | CDC/Stacks library study |
| Central US prevalence (Missouri, ~39°N) | 86.3 per 100,000 | CDC/Stacks library study |
| Northern US prevalence (Ohio, ~41°N) | 109.5 per 100,000 | CDC/Stacks library study |
| Highest regional prevalence (overall) | Northeast US | NMSS, 2019 national study |
Source: Hittle M et al., JAMA Neurology, 2023; CDC Stephen B. Thacker Library-archived study, “The Prevalence of Multiple Sclerosis in 3 US Communities”; National Multiple Sclerosis Society national prevalence study, 2019
The age distribution of multiple sclerosis confirms its reputation as a disease of early-to-middle adulthood, with nearly half of all US cases concentrated in the 45–64 age bracket. Within this range, a clear sex-based divergence emerges: women reach peak prevalence earlier, between ages 45 and 54, while men peak later, between ages 55 and 64. This pattern likely reflects both the earlier average age of onset in women and differences in diagnostic and disease progression timelines between the sexes, an area of ongoing NIH-funded research interest.
The geographic latitude gradient documented across multiple US-based studies remains one of the most consistent and scientifically intriguing findings in MS epidemiology. A federally archived CDC study comparing Texas, Missouri, and Ohio found prevalence rates that more than doubled from south to north — from 47.2 per 100,000 in Texas to 109.5 per 100,000 in Ohio. This latitude effect, also confirmed at the national level by the 2019 NMSS prevalence study identifying the Northeast as the region of highest overall MS burden, is widely believed to relate to reduced sun exposure, lower vitamin D levels, and increased viral transmission patterns in colder, more densely populated northern climates — though the precise causal mechanisms remain an active area of NIH-supported investigation.
Multiple Sclerosis Disease Course and Progression in the US 2024
Multiple sclerosis follows several distinct clinical courses, and understanding how patients transition between disease types is essential for treatment planning and long-term prognosis discussions.
MULTIPLE SCLEROSIS DISEASE COURSE DISTRIBUTION — US 2024
===========================================================
Relapsing-Remitting MS (initial) ████████████████████ ~85% at diagnosis
Primary Progressive MS ███░░░░░░░░░░░░░░░░░ 10–15% of all patients
Secondary Progressive MS conversion ████████████████░░░░ 50–90% within 10–25 yrs
(if untreated with DMTs)
| Disease Course Metric | Statistic | Source |
|---|---|---|
| Relapsing-remitting MS (RRMS) at initial diagnosis | Approximately 85% of patients | NMSS clinical data |
| Primary progressive MS (PPMS) share | 10–15% of all MS patients | NMSS, 2024 |
| Conversion to secondary progressive MS | 50–90% within 10–25 years if untreated | NMSS, 2024 |
| Effect of disease-modifying therapy on conversion | Substantially reduces conversion risk | NMSS-cited clinical research |
| Most common reason for MS hospitalization | Urinary tract infection | International Journal of MS Care, 2024 |
| Other leading hospitalization causes | Unknown neurological issues, relapse, falls | International Journal of MS Care, 2024 |
| Comorbid chronic conditions (elevated risk) | Lung disease, hypertension, high cholesterol, depression, anxiety | NMSS, 2020 |
Source: National Multiple Sclerosis Society (NMSS) clinical course data, 2024; International Journal of MS Care, 2024 (NIH-indexed publication)
The natural history of multiple sclerosis typically begins with the relapsing-remitting (RRMS) subtype, which accounts for roughly 85% of patients at the time of initial diagnosis. This form is characterized by distinct episodes of new or worsening symptoms followed by partial or complete recovery. However, the data on disease progression carries a critical clinical warning: without disease-modifying therapy, between 50% and 90% of RRMS patients will convert to secondary progressive MS within 10 to 25 years, a transition marked by a steadier, less reversible accumulation of disability. This statistic forms the central evidence base for current treatment guidelines that emphasize early initiation of disease-modifying therapy to delay or prevent this progression.
A smaller but clinically significant 10% to 15% of patients present with primary progressive MS (PPMS) from the outset, a form that involves gradual symptom worsening without the relapse-remission pattern seen in RRMS, and which has historically proven more resistant to available treatments. Beyond the neurological symptoms themselves, recent research published in the International Journal of MS Care found that urinary tract infections are the leading cause of MS-related hospitalizations, followed by undiagnosed neurological complications, disease relapses, and falls — a finding that highlights the importance of proactive bladder management and fall-prevention strategies in comprehensive MS care. The NMSS also confirms that MS patients face elevated rates of comorbid chronic conditions, including lung disease, high blood pressure, elevated cholesterol, depression, and anxiety, reinforcing the need for coordinated, whole-person care models.
Multiple Sclerosis Economic Burden in the US 2024
The financial cost of multiple sclerosis in the United States has been comprehensively quantified by NMSS-funded research published in Neurology, revealing a burden far larger than previously understood.
MULTIPLE SCLEROSIS ANNUAL ECONOMIC BURDEN — US 2024
======================================================
Total economic burden (2019) ████████████████████ $85.4 billion
Direct medical costs ████████████████░░░░ $63.3 billion (74%)
Indirect costs ████░░░░░░░░░░░░░░░░ $21.0 billion
Non-medical costs █░░░░░░░░░░░░░░░░░░░ $1.1 billion
PER-PATIENT BREAKDOWN:
Excess annual medical cost ████████████████████ $65,612
DMT cost share ████████████████░░░░ $35,154 (54% of direct costs)
Indirect/non-medical cost ████████░░░░░░░░░░░░ $18,542
| Cost Category | Amount (USD) | Source |
|---|---|---|
| Total US economic burden (2019) | $85.4 billion annually | Bebo B et al., Neurology, 2022 (NMSS-funded) |
| Direct medical costs | $63.3 billion (~74% of total) | Same study |
| Indirect costs (productivity loss, etc.) | ~$21.0 billion | Same study |
| Non-medical costs | $1.1 billion | Same study |
| Average excess medical cost per patient/year | $65,612 | Same study |
| Disease-modifying therapy (DMT) cost per patient | $35,154 (54% of direct costs) | Same study |
| DMT cost range by age/sex strata | $57,202 to $92,719 per patient/year | Same study |
| Average indirect/non-medical cost per patient | $18,542 (or $22,875 including caregiver costs) | Same study |
| Average total cost per patient (2022 study) | $88,487 per year | HealthCentral/Neurology, 2022 |
Source: Bebo B, Cintina I, LaRocca N, et al., “The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs,” Neurology, 2022 (NMSS-funded, peer-reviewed in the official journal of the American Academy of Neurology)
The landmark 2022 Neurology study, funded by the National Multiple Sclerosis Society, established that the total US economic burden of MS reached $85.4 billion in 2019 — a figure dramatically higher than earlier cost estimates, even after adjusting historical data for inflation. The largest cost driver by far is disease-modifying therapy, which alone accounts for $35,154 per patient annually, or roughly 54% of total direct medical costs. With per-patient DMT costs ranging as high as $92,719 annually for certain age and sex subgroups, the financial pressure on patients, insurers, and the federal healthcare system continues to intensify, particularly as DMT list prices have risen by 10% or more in most years over the past decade, according to research published in Therapeutic Advances in Neurological Disorders.
Beyond direct medical spending, indirect and non-medical costs add a further $22.1 billion annually, driven primarily by lost productivity, premature death, presenteeism, and absenteeism among both patients and their caregivers. When caregiver costs are factored in, the average indirect and non-medical burden rises to $22,875 per patient, highlighting how multiple sclerosis imposes financial strain not only on the individuals diagnosed but on their broader support networks as well. A 2020 NMSS survey further found that 40% of people living with MS reported affordability concerns significant enough to affect their ability to consistently access disease-modifying therapy — a finding that has fueled ongoing policy debates about the need for federal price negotiation authority over high-cost specialty medications in the United States.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
